Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 222Carcinoma, Renal Cell 84Liver Neoplasms 68Neoplasms 53Leukemia, Myeloid, Acute 37Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 29Melanoma 24Kidney Neoplasms 22Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Thyroid Neoplasms 13Recurrence 13Glioblastoma 13Colorectal Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

pembrolizumab 10Cisplatin 9Cetuximab 9Paclitaxel 5Radiotherapy 4Nivolumab 4Fluorouracil 4zalutumumab 3Docetaxel 3Taxes 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Gefitinib 2Cyclophosphamide 2Carboplatin 2temsirolimus 1sintilimab 1poly ICLC 1osimertinib 1fludarabine phosphate 1fludarabine 1enzalutamide 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1abemaciclib 1Vorinostat 1Sorafenib 1Risk Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Sorafenib × Clear all
NCT00815295 2014-12-08

Study of Sorafenib/Cetuximab in Head and Neck Cancer

Duke University

Phase 1/2 Completed
31 enrolled 11 charts

Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡